What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Tuberculosis
- Disease
Keertan Dheda focuses on Tuberculosis, Immunology, Mycobacterium tuberculosis, Internal medicine and Tuberculosis diagnosis.
His Tuberculosis research is multidisciplinary, incorporating elements of Cohort study and Intensive care medicine.
Keertan Dheda has included themes like Tuberculin and Latent tuberculosis in his Immunology study.
The Mycobacterium tuberculosis study combines topics in areas such as Rifampicin, Virology, T cell, Immunosuppression and Drug resistance.
His study in Internal medicine is interdisciplinary in nature, drawing from both Moxifloxacin and Surgery.
His Extensively drug-resistant tuberculosis research includes themes of Culture conversion and Epidemiology.
His most cited work include:
- Real-time RT-PCR normalisation; strategies and considerations (1399 citations)
- Real-time RT-PCR normalisation; strategies and considerations (1399 citations)
- Validation of housekeeping genes for normalizing RNA expression in real-time PCR (841 citations)
What are the main themes of his work throughout his whole career to date?
Keertan Dheda mostly deals with Tuberculosis, Immunology, Internal medicine, Mycobacterium tuberculosis and Sputum.
His research integrates issues of Surgery, Drug resistance and Intensive care medicine in his study of Tuberculosis.
His Drug resistance research is multidisciplinary, incorporating elements of Bedaquiline and Rifampicin.
His research investigates the link between Immunology and topics such as Latent tuberculosis that cross with problems in Tuberculin.
His Internal medicine study combines topics in areas such as Gastroenterology and Lipoarabinomannan.
His Mycobacterium tuberculosis research incorporates themes from Bronchoalveolar lavage, Interleukin 4 and Virology.
He most often published in these fields:
- Tuberculosis (86.09%)
- Immunology (42.60%)
- Internal medicine (42.16%)
What were the highlights of his more recent work (between 2017-2021)?
- Tuberculosis (86.09%)
- Internal medicine (42.16%)
- Mycobacterium tuberculosis (39.74%)
In recent papers he was focusing on the following fields of study:
Keertan Dheda spends much of his time researching Tuberculosis, Internal medicine, Mycobacterium tuberculosis, Bedaquiline and Intensive care medicine.
Keertan Dheda combines subjects such as Immunology and Drug resistance with his study of Tuberculosis.
His Immunology study incorporates themes from Bacillus and Human lung.
His study focuses on the intersection of Internal medicine and fields such as Isoniazid with connections in the field of Rifampicin.
The study incorporates disciplines such as Minimum inhibitory concentration, Whole genome sequencing, Host, Interleukin 4 and Computational biology in addition to Mycobacterium tuberculosis.
His research in Intensive care medicine intersects with topics in Community-acquired pneumonia, MEDLINE, Disease, Cause of death and Extensively drug-resistant tuberculosis.
Between 2017 and 2021, his most popular works were:
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. (626 citations)
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis (193 citations)
- Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis (131 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Tuberculosis
Keertan Dheda mainly investigates Tuberculosis, Internal medicine, Mycobacterium tuberculosis, Bedaquiline and Intensive care medicine.
His Tuberculosis study frequently draws connections between related disciplines such as Drug resistance.
In his research, Interim analysis and Cohort is intimately related to Vaccine efficacy, which falls under the overarching field of Internal medicine.
His studies deal with areas such as Effector, Intracellular, Cell biology and Gene knockdown as well as Mycobacterium tuberculosis.
His Bedaquiline research focuses on subjects like Pharmacotherapy, which are linked to Pretomanid and Dosing.
He has researched Intensive care medicine in several fields, including MEDLINE, Disease, Disease burden, Extensively drug-resistant tuberculosis and Prospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
